Genta, Inc (fka GNTAQ)

[The Holder]

Genta has met all of the requests from the FDA in order to receive approval of Genasense for the treatment of CLL, as specified by the FDA.

Please read slides 18 and 19 from the following link to get yourself up to speed on why the appeal was submitted by Genta leadership. Genta chose the second option from slide 18 and resubmitted the NDA. Start the media player on the left at 11 minutes *may have to copy/paste link*

http://webcastingplayer.corporate-ir.net/player/LrgPlayer.aspx?EventId=2079510&StreamId=1260249&TI%20K={8CEC9688-9089-484E-ABC1-DBB417AFD647}&RGS=1&override=lrg

Not only this, but the Agenda Trial is producing incredible confirmatory data of a prior phase III clinical study. It's the company's #1 focus and is going to support world-wide application of Genasense in the treatment of Melanoma.